ExonHit licenses Merck rights to RNA splicing microarray patent

ExonHit Therapeutics S.A., a drug and diagnostic discovery company, has announced that Merck & Co., Inc. has been granted a non-exclusive license to rights for research only under Patent US 6,881,571.

It is not anticipated that the revenues received by ExonHit from Merck under this agreement will exceed US$150,000 per year.

Patent US 6,881,571, entitled "Qualitative Differential Screening", was granted on April 19, 2005 and has claims directed to microarrays optimized for the monitoring of RNA splicing events.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
A faster, cheaper method to detect immune autoantibodies in whole blood